Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, NEU, and CD340, is a type I membrane glycoprotein and belongs to the epidermal growth factor (EGF) receptor family. ERBB2 has been found to be amplified with an increased copy number in several cancers. Amplification of ERBB2 promotes tumorigenesis and pathogenesis of several human cancers. Recently, in breast cancer patients without ERBB2 gene amplification, activating ERBB2 mutations have also been identified. ERBB2 is altered in 4.98% of all cancers with breast invasive ductal carcinoma, lung adenocarcinoma, colon adenocarcinoma, bladder urothelial carcinoma, and invasive breast carcinoma having the greatest prevalence of alterations.
Host species: Humanized
Isotype: IgG1-Kappa
Applications: Research Grade Runimotamab Biosimilar
Expression system: XtenCHO
Applications: SDS-PAGE,WB,ELISA,Immunogen,Bioactivity testing in progress
Expression system: Mammalian cells
Accession: P04626
Protein length: Met1-Thr652
Host species: Humanized
Isotype: IgG1-kappa
Applications: Research Grade Pertuzumab Biosimilar
Expression system: XtenCHO
Host species: Humanized
Isotype: IgG1-kappa
Applications: Research Grade Zenocutuzumab Biosimilar
Expression system: XtenCHO
Host species: Humanized
Isotype: IgG1-kappa
Applications: Research Grade Disitamab Biosimilar
Expression system: XtenCHO
Host species: Chimeric
Isotype: IgG1-kappa
Applications: Research Grade Margetuximab Biosimilar
Expression system: XtenCHO
Host species: Humanized
Isotype: IgG1-kappa/scFv-h-CH2-CH3
Applications: Research Grade Zanidatamab Biosimilar
Expression system: XtenCHO
